Thiazolidinediones and their Fluid-Related Adverse Effects
- 1 January 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 30 (9), 741-753
- https://doi.org/10.2165/00002018-200730090-00002
Abstract
Thiazolidinediones (TZDs) or glitazones are agents that are widely used for the treatment of type 2 diabetes mellitus. These drugs have a multitude of therapeutic effects including reduction in insulin resistance and hyperglycaemia, anti-inflammatory effects and amelioration of hypertension, microalbuminuria and hepatic steatosis. The TZD molecular target, peroxisome proliferator-activated receptor γ (PPARγ), a nuclear transcription factor, is expressed diffusely in humans, including many tissues comprising the cardiovascular and renal systems. This suggests a potential for TZDs to elicit perturbing effects on these systems, which are independent of their effects on glucose and lipid metabolism. One of the most common adverse effects of TZDs is fluid retention, which can result in, or exacerbate, oedema and congestive heart failure (CHF). The frequency of peripheral oedema is approximately 5% when TZDs are used in mono-or combination oral therapy, and about 15% when used with insulin. Patients with type 2 diabetes are at high risk of myriad morbid complications, including CHF. The development of CHF, particularly in the elderly, is a harbinger of premature mortality. TZD-induced oedema is largely peripheral, may have its origins in changes in haemodynamics, with some contribution from molecules, which regulate cell and tissue permeability (e.g. vascular endothelial growth factor and protein kinase Cβ), and remains the preponderant manifestation of TZD-induced fluid retention even in those with existing heart failure. Preclinical and pilot clinical data attest to the fact that at least part of the fluid retention derives from a direct effect of TZDs on sodium reabsorption via the renal medullary collecting duct, a mechanism that is sensitive to diuretic agents that have this nephron segment as their site of action, in whole or in part (spironolactone, amiloride and hydrochlorothiazide). Our review suggests various potential clinical strategies by which TZD-induced fluid retention might be effectively monitored and addressed.Keywords
This publication has 86 references indexed in Scilit:
- Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255Diabetes, 2007
- Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous StrokeStroke, 2007
- Combined Use of Rosiglitazone and Fenofibrate in Patients With Type 2 DiabetesDiabetes, 2007
- Effect of Various Diuretic Treatments on Rosiglitazone-Induced Fluid RetentionJournal of the American Society of Nephrology, 2006
- Thiazolidinedione Use and Bone Loss in Older Diabetic AdultsJournal of Clinical Endocrinology & Metabolism, 2006
- Insulin Sensitizing Pharmacotherapy for Prevention of Myocardial Infarction in Patients With Diabetes MellitusThe American Journal of Cardiology, 2006
- Pivotal role of peroxisome proliferator–activated receptor γ (PPARγ) in regulation of erythroid progenitor cell proliferation and differentiationExperimental Hematology, 2005
- Troglitazone and liver injury: In search of answersHepatology, 2005
- Amiloride and its analogs as tools in the study of ion transportThe Journal of Membrane Biology, 1988
- Role of diabetes in congestive heart failure: The Framingham studyThe American Journal of Cardiology, 1974